This marks a significant expansion of Clearside’s suprachoroidal therapy platform, which uses its patented SCS Microinjector® for targeted drug delivery to the back of the eye. Clearside's CEO ...
Clearside Biomedical's ARCATUS® NDA Accepted for Review in China for Uveitic Macular Edema Treatment
This NDA is based on positive results from a Phase 3 clinical trial in China, and ARCATUS, known as XIPERE® in the U.S., is the first approved suprachoroidal therapy for UME. The treatment uses ...
Clearside Biomedical (CLSD) reported that Arctic Vision’s New Drug Application or NDA for arcatus for the treatment of uveitic macular edema ...
Alpharetta, Georgia Wednesday, February 12, 2025, 16:30 Hrs [IST] ...
The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related ...
This drug, designed to treat uveitic macular edema (UME), leverages Clearside's SCS Microinjector® for delivery to the eye's suprachoroidal space. The company, currently valued at approximately $ ...
Clearside Biomedical, Inc. (NASDAQ:CLSD), currently valued at $81.15 million, is a biotechnology company focused on developing innovative therapies for blinding eye diseases using its proprietary SCS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback